The quick version:
NewLimit raised $435 million in Series C funding, led by Founders Fund.
The startup, co-founded by Coinbase CEO Brian Armstrong, works on epigenetic reprogramming to restore youthful cell function.
It is one of the largest recent bets on the longevity category.
The bet
NewLimit, co-founded by Coinbase CEO Brian Armstrong, closed a $435 million Series C led by Founders Fund. The company is working on medicines that use epigenetic reprogramming to restore youthful function in old cells. In plain terms, it is trying to make aging cells behave young again.
https://www.youtube.com/watch?v=isd2y37j8v4
Why investors are in
Longevity has gone from fringe to fundable. A $435 million round at Series C signals that serious capital now believes the science has a real shot, and that the market for it would be enormous. It also shows founders from one industry, in this case crypto, backing ambitious bets in another.
The bigger picture
Frontier science is having a funding moment while ordinary software faces a tighter market. The split is the story of 2026: hard, deep, defensible work gets backed aggressively, while incremental products fight for scraps.
Founders on Reddit keep asking where the money went, and the honest answer is that it went toward problems that are genuinely hard.
Quick Links: